Related Experiment Videos
Netilmicin: clinical efficacy, tolerance, and toxicity
Abstract:
Netilmicin, a new aminoglycoside antibiotic, has increased in vitro bactericidal activity against many strains of Enterobacteriaceae as compared to other aminoglycosides. It is a poor substrate for some of the common gentamicin-inactivating enzymes, and it has minimal toxicity in experimental animals. In 27 hospitalized patients, clinical cure was achieved in all, and the initial infecting organism persisted in only one. Therapeutic serum and urine levels were easily obtained in most patients. No ototoxicity was observed in two patients whose treatment required inordinately high serum levels and in whom other risk factors were present. Ototoxicity in 1 of 21 patients studied was unilateral, partially reversible, and not associated with high serum levels. Although nephrotoxicity occurred in 4 of 25 patients (16%), other host factors could have accounted for the toxicity in two patients. A new observation, not noted with other aminoglycoside antibiotics, was the elevation of serum alkaline phosphatase in 43% of the patients studied.
Insights
Netilmicin, a novel aminoglycoside antibiotic, demonstrates potent in vitro activity against Enterobacteriaceae and shows promising clinical efficacy in hospitalized patients. While generally well-tolerated, potential nephrotoxicity and a unique observation of elevated alkaline phosphatase warrant further investigation.
Area of Science:
- Pharmacology
- Microbiology
- Clinical Medicine
Background:
- Aminoglycoside antibiotics are crucial for treating serious bacterial infections.
- Emerging resistance to existing aminoglycosides necessitates the development of new agents.
- Netilmicin is a novel aminoglycoside antibiotic with a distinct resistance profile.
Purpose of the Study:
- To evaluate the in vitro bactericidal activity of netilmicin against Enterobacteriaceae.
- To assess the clinical efficacy and safety profile of netilmicin in hospitalized patients.
- To identify any unique adverse effects associated with netilmicin treatment.
Main Methods:
- In vitro susceptibility testing of netilmicin against various Enterobacteriaceae strains.
- Clinical trial involving 27 hospitalized patients with infections treated with netilmicin.
- Monitoring of serum and urine drug levels, clinical outcomes, and adverse events, including ototoxicity and nephrotoxicity.
Main Results:
- Netilmicin exhibited enhanced in vitro bactericidal activity compared to other aminoglycosides against many Enterobacteriaceae strains.
- All 27 patients achieved clinical cure, with only one instance of persistent infection.
- Therapeutic drug levels were readily achieved; minimal ototoxicity was observed, with one case of unilateral, partially reversible toxicity.
- Nephrotoxicity occurred in 16% of patients, with potential confounding host factors.
- Elevated serum alkaline phosphatase was observed in 43% of patients, a novel finding for aminoglycosides.
Conclusions:
- Netilmicin is a highly effective antibiotic against Enterobacteriaceae with a favorable clinical outcome profile.
- The drug demonstrates a potentially improved safety profile regarding ototoxicity compared to older aminoglycosides.
- Nephrotoxicity remains a consideration, and further research into the significance of elevated alkaline phosphatase is warranted.